Polyrizon Ltd trading halted, news pending
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
8 minutes ago
- Business Insider
Adaptimmune Therapeutics Stock (ADAP) Rockets 50% on CCO Severance Agreement
Adaptimmune Therapeutics (ADAP) stock rocketed higher on Monday after the clinical-stage biopharmaceutical company reached a severance agreement with former Chief Commercial Officer Cintia Piccina. Under the terms of this agreement, Piccina will receive 12 months of pay, $473,800, in a lump-sum payment. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Piccina will also continue to be able to benefit from the Employee 2016 Share Option Scheme. This will allow her to exercise vested options until January 30, 2032. The former CCO was also permitted a 'period of 12 months from the Separation Date to exercise any other Market Value Options that have vested by the Separation Date.' Piccina was terminated as the CCO of Adaptimmune Therapeutics on August 8, 2025. The reason for this was redundancy. Piccina's severance agreement with the company will go into effect on August 23, 2025. Adaptimmune Therapeutics Stock Movement Today Adaptimmune Therapeutics stock was up 47.23% in pre-market trading on Monday, following an 18.38% fall on Friday. The shares have also decreased 88.98% year-to-date and 94.69% over the past 12 months. Today's news saw heavy trading of ADAP stock, with some 270 million shares traded, compared to a three-month daily average of about 38 million units. Is Adaptimmune Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Adaptimmune Therapeutics is Moderate Sell, based on four Hold and two Sell ratings over the past three months. With that comes an average ADAP stock price target of 35 cents, representing a potential 488.24% upside for the shares.
Business Insider
9 minutes ago
- Business Insider
Who Is TipRanks' All-Star Analyst on Microsoft Stock (MSFT)?
The TipRanks All-star Analyst of the Day title goes to analyst Brent Thill of research firm Jefferies. Remarkably, Thill ranks #241 out of the 9,978 Wall Street analysts tracked by TipRanks. One of the key stocks in his coverage is Microsoft (MSFT), for which he is the Best analyst over a one-year time frame. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Microsoft is a multinational technology company known for its software products, including the Windows operating system and Microsoft Azure cloud computing services. For a thorough assessment of the stock, go to TipRanks' Stock Analysis page. When we look at Thill's recommendation for Microsoft stock, we see that he has had a 97% success rate by holding the stock for one year. Plus, he has earned an average return of 25.90% during that period. On an overall basis, copying Thill's trades and holding them for a year would give you an average return of 13%, with 64% of your trades generating a profit. Not Just MSFT Thill primarily focuses on covering the technology sector in the U.S. market. Importantly, his most profitable rating to date was a Buy on Meta (META), a social media and technology company that owns platforms like Facebook, Instagram, and WhatsApp. The analyst earned a massive 215.9% return on the call between November 09, 2022 and November 09, 2023. Following phenomenally successful analysts' ratings can add profit to your portfolio. Find the best analyst to follow for any stock by scrolling down to the ' Best Analyst Covering ' feature on its Analyst Forecast page. Top Analysts on TipRanks.
Business Upturn
41 minutes ago
- Business Upturn
Kernex Microsystems shares rise over 2% after bagging Rs 151 crore KAVACH order from West Central Railway
By Aditya Bhagchandani Published on August 19, 2025, 10:44 IST Shares of Kernex Microsystems (India) Ltd gained over 2% in Monday's trade after the company announced a fresh order win for the Indian Railways' indigenous KAVACH Automatic Train Protection (ATP) system. At 10:43 am, the stock was trading at ₹1,076 apiece on the NSE, up 2.31% (₹24.30) from the previous close of ₹1,051.70. During the session, the stock touched a high of ₹1,079.70 and a low of ₹999.20. Kernex currently commands a market capitalisation of ₹18.10 billion and has delivered sharp gains from its 52-week low of ₹621.55, though still off its high of ₹1,580. The company, through its Kernex–KEC Consortium, secured an order worth ₹151.41 crore (including GST) from West Central Railway, Bhopal Division. The scope of work involves deployment of the KAVACH ATP system on the UHF backbone along with optical fibre cable (OFC) and route diversity. The project will be completed in 600 days across sections including Itarsi–Khandwa and Bina–Ruthiyai . With this contract, Kernex's cumulative KAVACH order book since April 2024 has risen to ₹3,136.53 crore, underscoring strong momentum in the rail safety modernisation drive. Kernex, a niche player in railway safety and signalling solutions, continues to benefit from the government's aggressive push towards rail safety. Analysts say the company's expanding execution pipeline could further support stock performance, though valuations remain on the higher side with a P/E ratio of 36.03. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
